

# THE AMERICAN JOURNAL OF PSYCHIATRY

In This Issue

A44

2006 2510 Learning Resource Center  
and Library  
CHRISTIAN UNIVERSITY OF TAIWAN

## Perspectives

### Editorials

- 353 **Targeting Schizophrenia Research to Patient Outcomes**  
William T. Carpenter, Jr.
- 356 **Understanding the Glass Ceiling for Functional Outcome in Schizophrenia**  
Cameron S. Carter
- 359 **Stimulant Medications: How to Minimize Their Reinforcing Effects?**  
Nora D. Volkow
- 362 **Are We Still Talking to Our Patients With Schizophrenia?**  
Samuel J. Keith

### Reviews and Overviews

- 365 **Cognitive Behavior Therapy for Schizophrenia**  
Douglas Turkington, David Kingdon, and Peter J. Weiden

### Introspections

- 374 **A Tension to Detail**  
Samuel G. Siris

### Treatment in Psychiatry

- 376 **The Schizophrenia Prodrome**  
Tanya White, Afshan Anjum, and S. Charles Schulz

### Clinical Case Conference

- 381 **The Development of the Self in the Era of the Internet and Role-Playing Fantasy Games**  
Sara E. Allison, Lisa von Wahlde, Tamra Shockley, and Glen O. Gabbard

### Images in Psychiatry

- 386 **Abraham Arden Brill, 1874–1948**  
Essay by Arnold D. Richards and Paul W. Mosher

## New Research

### Articles

- 387 **PET Study Examining Pharmacokinetics, Detection and Likeability, and Dopamine Transporter Receptor Occupancy of Short- and Long-Acting Oral Methylphenidate**  
Thomas J. Spencer, Joseph Biederman, Patrick E. Ciccone, Bertha K. Madras, Darin D. Dougherty, Ali A. Bonab, Elijah Livni, Dolly A. Parasrampur, and Alan J. Fischman
- 396 **A PET Study Evaluating Dopamine D<sub>2</sub> Receptor Occupancy for Long-Acting Injectable Risperidone**  
Gary Remington, David Mamo, Alain Labelle, Jeffrey Reiss, Chekkera Shammi, Erik Mannaert, Steve Mann, and Shitij Kapur
- 402 **A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Maintenance Treatment in Children and Adolescents With Disruptive Behavior Disorders**  
Magali Reyes, Jan Buitelaar, Paz Toren, Ilse Augustyns, and Marielle Eerdeken
- 411 **Barriers to Employment for People With Schizophrenia**  
Robert Rosenheck, Douglas Leslie, Richard Keefe, Joseph, McEvoy, Marvin Swartz, Diana Perkins, Scott Stroup, John K. Hsiao, Jeffrey Lieberman, and CATIE Study Investigators Group
- 418 **Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms**  
Christopher R. Bowie, Abraham Reichenberg, Thomas L. Patterson, Robert K. Heaton, and Philip D. Harvey
- 426 **The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity**  
Richard S.E. Keefe, Margaret Poe, Trina M. Walker, Joseph W. Kang, and Philip D. Harvey
- 433 **Prognostic Variables at Intake and Long-Term Level of Function in Schizophrenia**  
Steven J. Siegel, Farzin Irani, Colleen M. Brensinger, Christian G. Kohler, Warren B. Bilker, J. Daniel Ragland, Stephen J. Kanes, Ruben C. Gur, and Raquel E. Gur

- 442 Impairment in the Specificity of Emotion Processing in Schizophrenia**  
Frank Schneider, Ruben C. Gur, Kathrin Koch, Volker Backes, Katrin Amunts, N. Jon Shah, Warren Bilker, Raquel E. Gur, and Ute Habel
- 448 Social Perception as a Mediator of the Influence of Early Visual Processing on Functional Status in Schizophrenia**  
Mark J. Sergi, Yuri Rassovsky, Keith H. Nuechterlein, and Michael F. Green
- 455 Functional and Structural Deficits in Brain Regions Subserving Face Perception in Schizophrenia**  
Toshiaki Onitsuka, Margaret A. Niznikiewicz, Kevin M. Spencer, Melissa Frumin, Noriomi Kuroki, Lisa C. Lucia, Martha E. Shenton, and Robert W. McCarley
- 463 Abnormalities of Thalamic Activation and Cognition in Schizophrenia**  
Jessica Andrews, Lei Wang, John G. Csernansky, Mokhtar H. Gado, and Deanna M. Barch
- 470 Sex Differences in Language Dysfunction in Schizophrenia**  
Deborah J. Walder, Larry J. Seidman, Nicole Cullen, Jessica Su, Ming T. Tsuang, and Jill M. Goldstein
- 478 Regional Brain Morphometry in Patients With Schizophrenia or Bipolar Disorder and Their Unaffected Relatives**  
Colm McDonald, Nicolette Marshall, Pak C. Sham, Edward T. Bullmore, Katja Schulze, Ben Chapple, Elvira Bramon, Francesca Filbey, Seema Quraishi, Muriel Walshe, and Robin M. Murray
- 488 Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers**  
Juan Francisco Artaloytia, Celso Arango, Adrienne Lahti, Javier Sanz, Ana Pascual, Pedro Cubero, David Prieto, and Tomás Palomo
- 494 Sildenafil in the Treatment of Antipsychotic-Induced Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Two-Way Crossover Trial**  
Rajesh Gopalakrishnan, K.S. Jacob, Anju Kuruvilla, B. Vasantharaj, and Jacob K. John
- 500 Assessment of Therapeutic Misconception in Older Schizophrenia Patients With a Brief Instrument**  
Laura B. Dunn, Barton W. Palmer, Monique Keehan, Dilip V. Jeste, and Paul S. Appelbaum
- 507 Association Between the CCR5 32-bp Deletion Allele and Late Onset of Schizophrenia**  
Henrik Berg Rasmussen, Sally Timm, August G. Wang, Karen Sæby, Henrik Lublin, Mogens Fenger, Ralf Hemmingsen, and Thomas Werge
- 512 Improving the Accuracy of the Diagnosis of Schizophrenia by Means of Virtual Reality**  
Anna Sorkin, Daphna Weinshall, Ilan Modai, and Avi Peled

- 521 Association of Schizophrenia and Autoimmune Diseases: Linkage of Danish National Registers**  
William W. Eaton, Majella Byrne, Henrik Ewald, Ole Mors, Chuan-Yu Chen, Esben Agerbo, and Preben Bo Mortensen

## Brief Reports

- 529 DRD2 Promoter Region Variation as a Predictor of Sustained Response to Antipsychotic Medication in First-Episode Schizophrenia Patients**  
Todd Leřcz, Delbert G. Robinson, Ke Xu, Jenny Ekholm, Serge Sevy, Handan Gunduz-Bruce, Margaret G. Wöerter, John M. Kane, David Goldman, and Anil K. Malhotra
- 532 Dysbindin Genotype and Negative Symptoms in Schizophrenia**  
Pamela DeRosse, Birgit Funke, Katherine E. Burdick, Todd Lencz, Jenny M. Ekholm, John M. Kane, Raju Kucherlapati, and Anil K. Malhotra
- 534 BDNF Val66Met Polymorphism and GAD<sub>67</sub> mRNA Expression in the Prefrontal Cortex of Subjects With Schizophrenia**  
Takanori Hashimoto and David A. Lewis
- 537 No Evidence for an Effect of COMT Val158Met Genotype on Executive Function in Patients With 22q11 Deletion Syndrome**  
Bronwyn Glaser, Martin Debbane, Christine Hinard, Michael A. Morris, Sophie P. Dahoun, Stylianos E. Antonarakis, and Stephan Eliez
- 540 Cellular Basis of Reduced Cortical Reelin Expression in Schizophrenia**  
Sharon L. Eastwood and Paul J. Harrison
- 543 Antisaccade Performance in Monozygotic Twins Discordant for Schizophrenia: The Maudsley Twin Study**  
Ulrich Ettinger, Marco Picchioni, Mei-Hua Hall, Katja Schulze, Timothea Touloupoulou, Sabine Landau, Trevor J. Crawford, and Robin M. Murray

## Communications and Updates

### Letters to the Editor

- 546**
- 546** Correction: In the article "Myocarditis During Clozapine Treatment" (2006; 163:204–208)

### Book Forum

- 557**
- 562 Books Received**

### Other Items of Interest

- A11** Officers of the American Psychiatric Association
- A14** How to Activate Your Online Subscription

CONTENTS *continued on p. A34*